Key Players in the Taiwan Atherosclerosis Market | Insights & Market Overview 2026

Taiwan Atherosclerosis Market Overview

According to 6Wresearch, the Taiwan atherosclerosis market is positioned for momentous growth, prompted by a rapidly aging society and the increasing pervasiveness of metabolic syndromes. Atherosclerosis, identified by the build-up of fats and cholesterol in the artery walls, remains a leading contributor of cardiovascular-related issues, which ranks as the second leading cause of death in Taiwan.

The market is highly influenced by government initiatives, which targets control rate for hypertension, hyperglycaemia, and hyperlipidaemia. Along with this, a key trend shaping the future of this segment is the integration of digital health monitoring via different platforms to empower patient self-management.

Competitive Landscape

The competitive landscape of the Taiwan atherosclerosis industry is determined by the dominance of global biopharmaceutical giants that leverage Taiwan's robust clinical trial infrastructure and high healthcare standards. Dominant companies maintain a high market share by introducing advanced therapies and establishing updated clinical pathways. Furthermore, these companies invest towards medical education and focus on environmental risk factors, which are critical for overcoming atherosclerotic risk in the region.

Below is a list of leading players operating in the Taiwan Atherosclerosis Market:

1. AstraZeneca Taiwan

AstraZeneca is a dominant leader, with its portfolio of lipid-regulating medicines and anti-platelet therapies being widely prescribed under NHI coverage.

2. Pfizer Taiwan

Pfizer provides essential statins and cardiovascular medications that form the backbone of chronic management for atherosclerotic patients.

3. Sanofi Taiwan

Sanofi is a major player in the anti-thrombotic and PCSK9 inhibitor segments, focusing on reducing major adverse cardiovascular events.

4. Novartis Taiwan

Novartis maintains a strong presence through its innovative siRNA-based lipid-lowering treatments and clinical research into inflammation-targeting therapies.

5. Bayer Taiwan

Bayer is a key player in providing oral anticoagulants and cardiovascular therapies targeting vascular protection in high-risk patients.

6. Daiichi Sankyo Taiwan

Daiichi Sankyo focuses on hypertension and lipid management, offering specialized medications tailored to the East Asian demographic.

7. Merck Sharp & Dohme (MSD) Taiwan

MSD provides critical cholesterol absorption inhibitors and continues to invest in therapies for atherosclerotic cardiovascular disease.

8. TTY Biopharm Company Limited

TTY Biopharm specializes in high-quality specialty medicines and is active in distributing cardiovascular treatments across hospital networks.

9. Standard Chemical & Pharmaceutical

Standard Chemical provides a wide range of affordable generic lipid-lowering and anti-hypertensive drugs.

10. Orient EuroPharma (OEP)

OEP is a local distributor and manufacturer that partners with global firms to bring specialized cardiovascular and metabolic medicines.